Rituximab treatment of myasthenia gravis: A systematic review

  title={Rituximab treatment of myasthenia gravis: A systematic review},
  author={R. Tandan and M. Hehir and W. Waheed and D. Howard},
  journal={Muscle & Nerve},
  • R. Tandan, M. Hehir, +1 author D. Howard
  • Published 2017
  • Medicine
  • Muscle & Nerve
  • Rituximab is a chimeric mouse/human anti‐CD20 monoclonal immunoglobulin. We reviewed the efficacy and safety of rituximab in 169 myasthenia gravis (MG) patients from case reports and series. Antibodies to the acetylcholine receptor (AChR) were present in 59% and muscle‐specific tyrosine kinase (MuSK) in 34%. Modified Myasthenia Gravis Foundation of America postintervention scale of minimal manifestations (MM) or better occurred in 44%, and combined pharmacologic and chronic stable remission in… CONTINUE READING
    90 Citations
    Rituximab as treatment for anti-MuSK myasthenia gravis
    • 52
    Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis.
    • 8
    Immunotherapy in myasthenia gravis in the era of biologics
    • 26
    Myasthenia Gravis Treatment Updates


    Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients
    • 47
    Response of patients with refractory myasthenia gravis to rituximab: a retrospective study
    • 106
    • PDF
    Long-lasting treatment effect of rituximab in MuSK myasthenia
    • 218
    Response to Therapy in Myasthenia Gravis with Anti‐MuSK Antibodies
    • 123
    Use and monitoring of low dose rituximab in myasthenia gravis
    • 70
    • PDF
    Rituximab for the Treatment of Thymoma-Associated and De Novo Myasthenia Gravis: 3 Cases and Review
    • 36